Stock Research: Procter & Gamble Health

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Procter & Gamble Health

BSE:500126 INE199A01012
17
  • Value
    75
  • Growth
    33
  • Safety
    Safety
    13
  • Combined
    21
  • Sentiment
    22
  • 360° View
    360° View
    17
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Procter & Gamble Health Limited is an India-based multinational consumer goods company focused on manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements for a healthy lifestyle. The company operates in healthcare, with brands including Polybion, Cosome, Evion, Neurobion, Seven Seas, Nasivion, and Livogen. Its products are sold in about 180 countries and territories throughout the world. In the last fiscal year, the company had 1336 employees, a market cap of $1130 millions, profits of $90 millions, and revenue of $138 millions.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 17 (better than 17% compared with alternatives), overall professional sentiment and financial characteristics for the stock Procter & Gamble Health are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Procter & Gamble Health. The only rank that is above average is the consolidated Safety Rank at 75, which means that the company has a financing structure that is safer than those of 75% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 13, which means that the share price of Procter & Gamble Health is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 33, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 22, which means that professional investors are more pessimistic about the stock than for 78% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 30-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 7 43 37
Growth
33 27 59 1
Safety
Safety
75 76 80 85
Sentiment
22 53 20 42
360° View
360° View
17 24 53 33
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
64 64 64 65
Opinions Change
50 50 50 50
Pro Holdings
n/a 76 41 61
Market Pulse
1 2 5 11
Sentiment
22 53 20 42
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
13 7 43 37
Growth
33 27 59 1
Safety Safety
75 76 80 85
Combined
21 16 75 23
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
49 34 49 36
Price vs. Earnings (P/E)
23 27 34 24
Price vs. Book (P/B)
8 14 14 20
Dividend Yield
1 1 71 64
Value
13 7 43 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
7 25 41 1
Profit Growth
84 41 62 46
Capital Growth
20 9 53 1
Stock Returns
93 65 63 9
Growth
33 27 59 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
85 82 82 86
Refinancing
24 32 38 42
Liquidity
86 88 88 88
Safety Safety
75 76 80 85

Similar Stocks

Discover high‑ranked alternatives to Procter & Gamble Health and broaden your portfolio horizons.

Cipla

NSEI:CIPLA
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Maruti Suzuki

NSEI:MARUTI
Country: India
Industry: Automobile Manufacturers
Size: Large
Full Stock Analysis

Dr. Reddy's

BSE:500124
Country: India
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

L&T Finance Holdings

BSE:533519
Country: India
Industry: Other Financial Services
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.